Jack Higgins sold $334k of IMNM
Chief Scientific Officer at Immunome Inc.. 13,200 shares at an average of $25.32, traded Sep 11, 2026, filed Sep 15, 2026.
Score components
- +15RoleOfficer
- +15Trade size$334k at market
- +5Share of holdings soldSold 17% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001993684-26-000008, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | MOption exercise Common Stock10b5-1 | +18,000 | $1.35 | $24k | 78,250 | 27 d ago |
| Sep 11, 2026 | SOpen-market sale Common Stock10b5-1 | -13,200 | $25.32 | $334k | 65,050 | 27 d ago |
| Sep 11, 2026 | GGift Common Stock10b5-1 | -8,800 | $0.00 | $0 | 56,250 | 27 d ago |
| Sep 11, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | +18,000 | $0.00 | $0 | 133,840 | 27 d ago |
Related signals
Other insiders at Immunome Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 37Weak | IMNMbuy Immunome Inc. | Jean Jacques Bienaime director | $47k 5,000 shares | +16% | |
| 48Moderate | Immunome Inc. | Jean Jacques Bienaime director | $61k 7,800 shares | +33% | |
| 76Notable | Immunome Inc. | Clay B Siegall President and CEO | $999k 137,100 shares | +20% | |
| 43Moderate | Immunome Inc. | Jean Jacques Bienaime director | $57k 7,000 shares | +42% | |
| 50Moderate | Immunome Inc. | Philip Tsai Chief Technology Officer | $104k 12,300 shares | +59% | |
| 61Notable | IMNMbuy Immunome Inc. | Clay B Siegall President and CEO | $1.2M 150,000 shares | +29% | |
| 50Moderate | Immunome Inc. | Philip Tsai Chief Technology Officer | $198k 21,000 shares | - | |
| 49Moderate | Immunome Inc. | Robert Lechleider Chief Medical Officer | $150k 15,805 shares | - | |
| 70Notable | Immunome Inc. | Clay B Siegall President and CEO | $962k 100,000 shares | +24% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.